Anti-TRAIL-R4 / TNFRSF10D / TRUNDD, clone 23T76

Antibody in PBS with 0.02% sodium azide, 50% glycerol and 0.4-0.5mg/ml BSA. TRAIL R4 antibody is a useful reagent for investigating apoptosis, immune regulation, and cancer biology. The encoded protein, TNFRSF10D (also known as TRUNDD or TRAIL receptor 4), is a member of the tumor necrosis factor receptor superfamily. Unlike TRAIL receptors that signal apoptosis, TRAIL R4 lacks a functional death domain and instead acts as a decoy receptor for TRAIL (TNF related apoptosis inducing ligand). By binding TRAIL without transmitting apoptotic signals, TNFRSF10D protects cells from TRAIL mediated cell death and modulates sensitivity to immune surveillance.TRAIL R4 is expressed in a variety of tissues and cell types, including immune cells and epithelial cells. Its expression pattern suggests a role in maintaining tissue homeostasis by preventing inappropriate activation of apoptosis. In addition, TRAIL R4 has been shown to activate pro survival pathways such as NF kappa B and PI3K Akt signaling, further supporting its function as a regulator of cell fate. These properties distinguish it from TRAIL receptors DR4 and DR5, which contain functional death domains and induce apoptosis.Research has linked TNFRSF10D to tumor biology. Overexpression of TRAIL R4 in cancer cells provides resistance to TRAIL mediated killing, allowing malignant cells to evade immune destruction. This mechanism contributes to tumor progression and therapeutic resistance in cancers such as colon, breast, and lung carcinoma. Because of this protective effect, TRAIL R4 is studied as both a biomarker and a potential target for overcoming resistance in TRAIL based therapies. Its role in modulating survival pathways also makes it relevant in studies of inflammation and immune regulation.At the molecular level, TRAIL R4 contains extracellular cysteine rich domains typical of TNF receptors but a truncated intracellular domain that lacks apoptotic signaling capacity. This structure enables it to compete with death inducing TRAIL receptors for ligand binding, thereby controlling the balance between apoptosis and survival. Functional studies indicate that TRAIL R4 can redirect TRAIL signaling toward non apoptotic outcomes, influencing proliferation and inflammatory responses.The TRAIL R4 antibody is widely used in western blotting, immunohistochemistry, immunofluorescence, and flow cytometry to measure protein expression and localization. These applications are critical for cancer research, apoptosis studies, and immune regulation. For scientists exploring tumor immune evasion, cytokine receptor signaling, or therapeutic interventions, the TRAIL R4 antibody provides a reliable detection tool. NSJ Bioreagents supplies validated antibodies that ensure reproducibility and accuracy in advanced molecular studies.